Former consultants for GlaxoSmithKline PLC urged a Pennsylvania federal court Friday to send back to state court their suit against the company alleging they landed in a Chinese prison after the business tricked them into investigating a whistleblower, saying GSK could not invoke federal jurisdiction after having argued to the contrary.
Pay-for-delay deals staving off generic competition have become a favorite target for lawmakers eager to be seen combating soaring pharmaceutical costs and for antitrust enforcers who believe consumers are hurt when drug companies agree to postpone the introduction of generics. Promoting such competition for biological therapies may be next on Washington's list.
Last year, a California jury punished Monsanto to the tune of almost $300 million after finding its popular weedkillers caused a man's cancer, and six months later, all eyes are on the next legal showdown over glyphosate. Here's what attorneys will be watching as the four-week trial kicks off Monday.
More than two dozen generic-drug companies have asked a Pennsylvania federal court to carve out allegations of an "overarching conspiracy" from sprawling multidistrict litigation brought by state attorneys general and private plaintiffs, arguing the price-fixing allegations fall short of asserting a single industrywide scheme.
A Pennsylvania drugmaker has agreed to pay $4 million to end False Claims Act allegations it tried to circumvent U.S. Food and Drug Administration fees by paying companies eligible for fee waivers to submit its new drug applications under their names, prosecutors announced Friday.
A former pharmaceutical sales representative has pled guilty for her role in what prosecutors say is an $8 million health care fraud scheme in which she personally pocketed more than $1 million.
Sika AG is reportedly eyeing the construction chemicals unit of German chemical giant BASF, Berkshire Hathaway is close to selling off its workers' compensation business to a group of insurance firms, and Centogene AG is mulling going public in New York.
Synergy Pharmaceuticals Inc. is facing challenges to its Chapter 11 plan disclosures from the U.S. Securities and Exchange Commission and the plaintiffs in a shareholder class action who say the plan shouldn't force parties to opt out of the litigation releases.
New York-based neurotechnology startup CTRL-labs said Friday that it has closed a $28 million funding round led by GV, the venture capital investment arm of Alphabet Inc., bringing its total amount of capital raised to date to $67 million.
Novartis Pharmaceuticals Corp. and Express Scripts Inc. have escaped a suit alleging they engaged in a kickback scheme after a New Jersey federal judge found that a former Novartis employee failed to back up his claims that the company illegally provided commercial discounts on multiple sclerosis drug Gilenya in exchange for Medicare Part D business.
Becky Wood, co-chair of the U.S. Food and Drug Administration practice at Sidley Austin LLP and former chief counsel of the FDA, tells Law360 she's tracking U.S. Supreme Court action on drug and device safety, eyeing new approaches to product approvals and fretting about political impacts on FDA recruiting.
Insys Therapeutics Inc. routinely lied to insurance companies, training employees to "ride the gray line" between truth and fiction in order to get expensive fentanyl prescriptions covered, a former manager testified Friday in Boston federal court during a trial for company brass accused of bribing doctors to prescribe the drug.
A Texas federal judge has rejected Baylor University and its research partner's request to declare a cancer therapy patent infringement case exceptional so they could be awarded attorneys' fees as the self-declared prevailing party.
The success of a lawsuit to add two American scientists to patents for Nobel Prize-winning cancer research will hinge on establishing that the pair’s research was significant to the ultimate invention, the Boston federal judge overseeing the case indicated Friday at closing arguments in an eight-day bench trial.
Squire Patton Boggs LLP and a lobbying subsidiary of Greenspoon Marder LLP are among the advisers of a new cannabis industry group chaired by former U.S. House Speaker John Boehner that aims to promote reforms in federal cannabis laws.
A putative class of investors alleged in New York federal court on Thursday that pharmaceutical research and development company WuXi PharmaTech kept them in the dark about plans to spin off subsidiaries following a $3.6 billion merger that took the company private.
Amgen struck an illegal deal with Teva Pharmaceuticals to pull a generic version of the calcium control drug Sensipar from the market after it had already netted $59 million in profits, according to a proposed class action filed in a Delaware court.
DLA Piper nabbed a new life sciences patent strategy group leader from Venable LLP and Baker McKenzie brought on a former Morgan Lewis & Bockius LLP attorney to lead its life sciences group, marking two of the latest shake-ups in firms' health and life sciences practices.
The U.K.’s fraud and bribery agency dropped two long-running investigations on Friday and announced that it will bring no charges against individuals at Rolls-Royce or GlaxoSmithKline because of a lack of evidence.
A Texas federal judge refused Thursday to upend a jury verdict clearing an allergy patient advocacy group of allegations that it participated in an anti-competitive scheme to lock remote treatment providers out of the market, saying there is nothing to show the jury ignored evidence of the group's alleged interference.
Effectively running a multistate cannabis business requires a dedicated commitment to developing and maintaining a robust regulatory enterprise risk management system involving legal compliance, finance, operations and technology, says Gary Kaminsky of Acreage Holdings.
We recently hatched a plan to test whether litigators could get blockchain ledger entries into evidence under the existing Federal Rules of Evidence, and we found a federal judge willing to help us, say attorneys Justin Steffen, Andrew Hinkes, Lisa Braganca, Christopher Veatch, Kashan Pathan and Jimmie Zhang.
In its recent rejection of the Ninth Circuit’s key 2013 holding in Stengel v. Medtronic, the Arizona Supreme Court gave new hope to defendants arguing that state law failure-to-warn claims are preempted by the Medical Device Amendments to the Food, Drug, and Cosmetic Act, say Colleen McElroy and Brendan Krasinski of DLA Piper LLP.
In the last month, divisions of the U.S. Department of Health and Human Services have taken three separate actions that collectively reflect continuing interest in facilitating high-value care delivery that goes far beyond traditional models, say attorneys at Ropes & Gray LLP.
There is a commercial imperative to illuminate the mystery of artificial intelligence. Doctors are hard-pressed to rely on machine recommendations that contradict their own medical judgment without a clear explanation, and banks cannot rely on lending algorithms that may be discriminating against classes of borrowers through hidden variables, says Danny Tobey of DLA Piper LLP.
In this monthly series, Amanda Brady of Major Lindsey & Africa interviews management from top law firms about the increasingly competitive business environment. Here we feature John Yoshimura, chief operating officer at McDermott Will & Emery LLP.
Organizations should seek to avoid discrimination, but they should also be wary of the idea that diverse teams function better than nondiverse teams, because this reasoning lacks evidence and can lead to a slippery slope, says J.B. Heaton of J.B. Heaton Research LLC.
Personal injury lawyers have set their sights on America’s pharmaceutical companies and opioid distributors, which they blame for a national health crisis. The cases these lawyers initiate may bear the names of states and municipalities, but are driven by law firms' pursuit of huge contingency fees, says Sherman Joyce of the American Tort Reform Association.
The U.S. Department of Health and Human Services' recent proposal to update the prescription drug discount safe harbor does not directly affect the price-setting activities of pharmaceutical manufacturers, but instead appears designed to affect prices indirectly by increasing transparency, say attorneys with Ropes & Gray LLP.
Inventor testimony inevitably forms a part of every generic drug company’s case in a Paragraph IV obviousness challenge under the Hatch-Waxman Act. This is odd because recent cases demonstrate that inventor testimony can damage a generic defendant’s case, says Michael Hogan of Caesar Rivise PC.